Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results PR Newswire NEW HAVEN, Conn., August 10, 2026 First extracellular protein degraders in the clinic demonstrate rapid and...
PR Newswire
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors PR Newswire NEW HAVEN, Conn., Aug. 6, 2026 Infinitum founder and Groq board director brings frontier AI and technology-investing expertise toBiohaven...
PR Newswire
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at...
PR Newswire
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload PR...
PR Newswire
Biohaven Announces Scientific Leadership Transitions
Biohaven Announces Scientific Leadership Transitions Biohaven Announces Scientific Leadership Transitions PR Newswire NEW HAVEN, Conn., July 9, 2026 David Pirman, Ph.D. promoted to Executive Vice President and Head of DiscoveryBruce Car, Ph.D. transitioning from Chief Scientific Officer to new role...
PR Newswire
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator PR Newswire NEW HAVEN, Conn., June 30, 2026 Enrollment complete in...
PR Newswire
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3...
PR Newswire
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks